On January 20, Maria S. Remedi, PhD and Colin G. Nichols, PhD had their perspective published in the American Diabetes Association’s diabetes journal, titled “Glucokinase Inhibition: A Novel Treatment for Diabetes?”
“Chronic hyperglycemia increases pancreatic β-cell metabolic activity, contributing to glucotoxicity-induced β-cell failure and loss of functional β-cell mass, potentially in multiple forms of diabetes.”
In the perspective, Remedi and Nichols widely discuss the concept of glycolysis, as an approach to improve insulin secretion in diabetes treatment. The novel, paradoxical and counterintuitive concept targets the first enzyme in glycolysis, which is glucokinase. The approach is intended to improve insulin secretion through maintaining glucose sensing and preservation of the functional β-cell mass.
Maria S. Remedi, Colin G. Nichols; Glucokinase Inhibition: A Novel Treatment for Diabetes?. Diabetes 1 February 2023; 72 (2): 170–174. https://doi.org/10.2337/db22-0731